We aimed to describe the relationship between changes in highsensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.
T he presence of diabetes mellitus (DM) is associated with an increased risk of both microvascular (retinopathy, nephropathy, or neuropathy) and macrovascular events (myocardial infarction [MI] , stroke, peripheral arterial disease). 1, 2 Furthermore, in patients with acute coronary syndrome (ACS), the presence of diabetes mellitus or hyperglycemia significantly increases the mortality and morbidity associated with that ischemic event. The magnitude of risk for macrovascular events varies widely. 3 Although clinical characteristics are useful in identifying patients at increased risk of both ischemic and heart failure events, the use of cardiovascular biomarkers in conjunction with clinical variables enhances the ability to classify the risk of adverse clinical outcomes. 4, 5 Ideal primary and secondary prevention strategies personalize interventions based on the risk of future events. High-sensitivity cardiac troponin (hsTn) has shown promise to identify patients with diabetes mellitus at high risk of cardiovascular events. [6] [7] [8] The EX-AMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) was a phase IIIb clinical outcomes trial designed to evaluate the cardiovascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 (DPP-4) inhibitor, in patients with type 2 DM (T2DM) stabilized after an ACS. 9, 10 Because of a robust serial sampling schedule in a well-characterized cohort of patients with established ischemic heart disease and T2DM, EXAMINE offers an opportunity to provide further granularity to the prognostic performance of hsTn in this population of patients, including to assess changes in hsTn over time and the relationship with outcomes. In addition, we sought to evaluate the cardiovascular safety of alogliptin in those patients at highest risk based on the assessment of hsTn.
METHODS Study Population and Design
The full details of the design, inclusion/exclusion criteria, and protocol of the EXAMINE trial have been published previously. 9 In brief, EXAMINE was a double-blind, placebo-controlled, noninferiority trial that randomized patients (n=5380) with T2DM and an ACS within 15 to 90 days before enrollment to treatment with alogliptin or placebo. 10 Patients were eligible for the trial if they had T2DM, glycohemoglobin between 6.5% and 11% at the time of screening (or between 7% and 11% if they were on insulin), and were receiving treatment for DM with drugs other than a glucogen-like peptide-1 analogue or DPP-4 inhibitor. Patients were excluded if they had type 1 DM, end stage renal disease on dialysis, New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, significant valvular heart disease, or severe uncontrolled hypertension. The median follow-up time was 18 months.
The Institutional Review Board or Ethics Committee for each participating institution reviewed and approved the trial. All patients randomized in the trial provided informed consent, including for the biomarker study.
End Points
The primary end point for the trial was the composite end point of cardiovascular death, nonfatal MI, or nonfatal stroke. Based on earlier work with hsTnI in patients with stabilized ischemic heart disease, the end point of cardiovascular death or heart failure (HF) and the individual components were of particular interest for the biomarker substudy. We therefore analyzed each of these end points as well as the composite of cardiovascular death or MI. A clinical events committee that was unaware of the treatment randomization adjudicated all components of the primary and secondary efficacy end points according to prespecified definitions that were based on the standardized definitions recommended by the U.S. Food and Drug Administration. 10, 11 The end point of HF was prospectively adjudicated, requiring hospitalization along with clinical evidence of and treatment for HF. 12 
Biomarker Analysis
Baseline hsTnI was measured using a high-sensitivity assay in 5230 patients randomized in the EXAMINE trial and repeated
Clinical Perspective
What Is New?
• High-sensitivity cardiac troponin I (hsTnI) is detectable in the majority (93%) of patients with type 2 diabetes mellitus stabilized >30 days after acute coronary syndrome.
• One in 6 of these patients will have hsTnI levels ˃99th percentile upper reference limit.
• hsTnI had a strong graded relationship with the incidence of subsequent major cardiovascular events.
• Changes in hsTnI ≤2 to 6 ng/L over 6 months were associated with a heightened risk of adverse outcomes, particularly cardiovascular death and heart failure.
• Alogliptin did not increase the risk of cardiovascular events, including hospitalization for heart failure, in a high-risk cohort of patients with elevated hsTnI.
What Are the Clinical Implications?
• Most patients with type 2 diabetes mellitus have stable values of hsTnI; however, almost 1 in 4 stable patients with type 2 diabetes mellitus have a ≥25% increase in hsTnI over 6 months.
• The stability of hsTnI in the majority of patients suggests that underlying structural heart disease rather than acute myocardial injury is the source of elevated hsTn.
• Serial measurements of hsTn may have a role in prevention strategies by either intensifying or prolonging therapy in patients at high risk of cardiovascular events or reducing or shortening therapy in patients at low risk of events.
at the month 6 visit in 4365 (88% of survivors to that visit). Blood was drawn and serum was isolated and frozen at -20° to -80°C at the local site until shipment to the central laboratory. Frozen samples were shipped to the Brigham Research/ Thrombolysis in Myocardial Infarction (TIMI) Clinical Trials Laboratory, where they were maintained at ≥-80°C. After thaw, the samples were centrifuged at 3000 relative centrifugal force for 30 minutes at 4°C. hsTnI was measured on the ARCHITECT i2000SR analyzer (Abbott Laboratories). This analyzer is a chemiluminescent microparticle immunoassay for hsTn that has a lower limit of detection of 1.9 ng/L (0.0019 ng/mL). 13 Patients who had hsTnI <1.9 were imputed to have hsTnI of 1.8 ng/L for analyses requiring continuous data. The upper reference limit (URL), defined as the 99th percentile in normal individuals, is 26 ng/L (0.026 ng/mL). 14 The total imprecision is <10% at this concentration. 15 Previous studies with this assay have suggested that an additional threshold between 4 and 7 ng/L may be useful in the evaluation of patients at risk for or with stable ischemic heart disease. [16] [17] [18] Sex-based cut points (99th percentile URL) have also been identified (≥34 ng/L for males, ≥16 ng/L for females) and were used in sensitivity analyses. 19 
Statistical Analysis
Baseline characteristics were compared across categories of hsTnI using the Wilcoxon rank-sum test for continuous variables and the χ-squared test for categorical variables. Event rates were determined using Kaplan-Meier estimations at 24 months unless otherwise noted. The present report focuses on the cohort of patients who were enrolled ≥30 days after the qualifying ACS so as to remove the potential confounding influence of detecting persistent elevation after the qualifying MI. hsTnI was assessed in ranges of concentration using prespecified thresholds (<1.9, 1.9-<10, 10-<26, ≥26 ng/L) based on our earlier work with this assay. 20 In addition, hsTnI was dichotomized at 6 ng/L, a value previously shown to have prognostic relevance.
The analysis of hsTnI concentration at 6 months was restricted to those patients without a recurrent cardiovascular event (MI, hospitalization for unstable angina, stroke, HF hospitalization) in the 30 days before the month 6 visit. Landmark analyses were performed starting at the month 6 visit through 24 months thereafter. A Cox proportional hazards model was used to assess the association between hsTnI and future cardiovascular events. The model adjusted for important potential confounders (age, sex, type of qualifying ACS event, time from index event, history of HF, hypertension, baseline glycohemoglobin, and estimated glomerular filtration rate). Comparisons between alogliptin and placebo were performed using a Cox proportional hazards model that included geographic region and baseline renal function as prespecified stratifying variables. Analyses were performed using SAS (Version 9.3).
RESULTS
Baseline characteristics stratified by concentration of hsTnI are shown in Table 1 for the cohort >30 days from the qualifying event (n=3808). Patients with higher concentrations of hsTnI were older, less likely to be female, and more likely to have a history of a qualifying MI (versus unstable angina), longer duration of T2DM, renal dysfunction, and HF.
Baseline hsTnI and Cardiovascular Outcomes
In this population of patients with T2DM and established coronary artery disease, hsTnI was detectable (≥1.9 ng/L) in the majority of patients (n=3557, 93%) and was ˃99th percentile URL in 16% (n=617). Analysis of the proportion of patients with hsTnI >URL according to the time from the index event showed that 29% of patients randomized between 15 and 30 days after ACS had hsTnI ≥26 ng/L. This proportion declined to 16% among those who were 30 to 60 days after the index event and was stable at 15% in patients between 60 and 90 days from the index event (Table I in the online-only Data Supplement).
A strong graded relationship occurred between a higher concentration of hsTnI at baseline and the incidence of major cardiovascular events ( Figure 1 ). After adjusting for potential confounders, the concentration of hsTnI at baseline was independently associated with the development of major cardiovascular events, with a rising pattern of risk that was apparent even at concentrations ˂99th percentile URL ( Figure 2 ). Moreover, patients with hsTnI ˃99th percentile URL were at 3-to 9-fold higher risk of suffering a major cardiovascular event ( Figure 2 ). Specifically, patients with T2DM who had levels of hsTnI that were ≥1.9 ng/L to <26 ng/L had an almost 3-fold increased risk of cardiovascular death, MI, or stroke compared with those with undetectable hsTnI (11.5% versus 4.1%; adjusted hazard ratio [HR], 2.86; 95% confidence interval [CI], 1.41-5.78; P=0.004). Sensitivity analyses using sex-specific cut points showed no meaningful difference in relative risk (Table II in 
Month 6 and Serial Assessment of hsTnI
Among stable patients without recent recurrent events, a strong positive, graded relationship occurred between hsTnI at 6 months and the incidence of major cardiovascular events thereafter (Table 2, Figure 3 ).
At 6 months, the median change in hsTnI concentration from baseline was -1.1 ng/L (interquartile range, -5.0, 0.8) with a distribution depicted in Figure I in the online-only Data Supplement. The median change was statistically similar regardless of sex, age, index event, or earlier HF (Table III in the online-only Data Supplement). Overall 11.7% of patients had an hsTnI ≥26 ng/L at 6 months. More specifically, of the 2638 patients with an hsTnI <26 ng/L at baseline (84%), 3.9% rose to ˃URL at 6 months. In contrast, among the 492 patients with an hsTnI ≥26 ng/L at baseline, 53% (n=262) remained elevated at 6 months. Evaluating the percentage (relative) change in hsTnI from baseline to 6 months, the majority of patients had either no change or a decline, whereas 21.5% of patients had ≥25% increase in hsTnI ( Figure II in the online-only Data Supplement). Baseline hsTnI and history of HF were the only independent predictors of the change in hsTnI from baseline to 6 months (P<0.001 for both), with higher baseline hsTnI and history of HF identifying patients more likely to have a decline by 6 months. The distribution of relative and absolute change values, taking into account the starting concentration, is shown in Table IV in the online-only Data Supplement. The majority of patients starting with a low concentration had no significant increase by 6 months, and relatively few in that cohort had absolute increases in hsTn >6 ng/L. In contrast, among those patients with starting concentrations ˃99th percentile URL, the majority had a decrease of hsTnI concentration of ≥50% and >6 ng/L.
Change in hsTnI and Cardiovascular Outcomes
Compared with patients with stably low values of hsTnI, patients with an elevated hsTnI at either baseline or 6 months had a significantly higher incidence of subsequent major cardiovascular events (Table 3, Figure 4 ). Patients who had hsTnI concentrations ≥99th percentile URL at any time were at high risk ( Figure 4 ). In particular, apparently clinically stable patients who nonetheless had hsTnI that rose from ˂99th percentile URL to ˃99th percentile URL from baseline to 6 months were at increased risk of cardiovascular death, MI, or stroke (28 Adjusted for age, sex, type of qualifying ACS, time from index ACS event, history of heart failure, hypertension, baseline glycohemoglobin and renal function (>30 days from ACS cohort). ACS indicates acute coronary syndrome; CVA, cerebrovascular accident; CVD, cardiovascular disease; hsTnI, high-sensitivity cardiac troponin I; and MI, myocardial infarction tion, when assessed as a percentage change from baseline values, patients with either a ≥25% to 50% or a ≥50% increase were at higher risk of cardiovascular events (HR, 1.59; and HR, 2.04, respectively; Table 4 ). When assessed based on an absolute change, patients with an increase ≥2 ng/L were found to have greater than double the risk of adverse cardiovascular outcomes (Table 4) . Similar outcomes were seen when restricting the analysis only to patients who were >60 days from the index ACS event (Tables V and VI in the online-only Data Supplement).
Change data stratified by baseline hsTnI concentration are shown in Table VII and Figure III in the online-only Data Supplement. It is notable that patients with an hsTnI ˃6 ng/L at baseline were at higher risk of major cardiovascular events than those <6 ng/L, irrespective of the magnitude of any change; however, a further gradient of risk was apparent depending on whether the patient showed a rising pattern by month 6 (Table VIII and 
DISCUSSION
In this analysis of the EXAMINE trial, we found that nearly all patients had a measurable concentration of hsTnI and that 1 out of 6 patients with T2DM with established ischemic heart disease (1-3 months after ACS) had hsTnI levels ˃99th percentile URL. Evaluating serial concentrations of hsTnI over time in this cohort with T2DM and established atherosclerosis, we also found that ≈ 1 in 4 stable patients had ≥25% increase in hsTnI over a 6-month period. In addition, the majority of patients had stable rather than declining values, including among those patients with a markedly elevated baseline concentration, pointing to the importance of chronic underlying structural heart disease rather than acute myocardial injury as a determinant of circulating hsTn in this population. It is notable that the small cohort of patients with undetectable hsTnI was at extremely low risk of future cardiovascular events despite their history of T2DM and ischemic heart disease. In contrast, patients with hsTnI ˃99th percentile URL at either baseline or 6 months were at considerably higher risk of major cardiovascular events. Moreover, those with intermediate increases in hsTnI concentration (2-6 ng/L) were at moderately higher risk of adverse cardiovascular events. Last, we found no evidence that treatment with alogliptin increased the risk of major cardiovascular events in this extremely high-risk cohort of patients identified by hsTnI.
Emerging Role of Cardiac Troponin in T2DM
These findings add to evidence supporting a potential role for hsTnI in the risk stratification of patients with T2DM, including those with established atherosclerosis. Serial assessments of hsTnI provided additional insight regarding the relationship of changes in hsTnI over time with prognosis.
Considered as an isolated measurement, both relatively early (4 weeks to 3 months) after stabilization from ACS and in the stable phase of ischemic heart disease at 6 months, hsTnI was a strong and independent predictor of future cardiovascular events. These findings are consistent with earlier studies in varied patient populations with T2DM, including population-based cohorts and low-risk patients with stable coronary artery disease. 6, 8, 17, 21, 22 In this study, we expand on these findings and demonstrate the relevance of serial sampling of hsTnI in patients with T2DM. Although most patients had stable values, nearly 1 in 6 without any clinically recognized manifestation of acute ischemia or HF had a concentration of hsTn that exceeded the URL for diagnosis of acute MI. Moreover, changes in hsTnI concentration over time were predictive of future cardiovascular events. Among the 23% of pa- ACS indicates acute coronary syndrome; CVD, cardiovascular disease; hsTnI, high-sensitivity cardiac troponin I; and KM, Kaplan Meier.
tients with a ≥25% increase in hsTn, the risk of subsequent major cardiovascular events (Table 4A ) was significantly higher than in patients with no change. Our results show that both relative and absolute changes can be used to identify a gradient of risk. For practical application with this hsTnI assay, an increased risk of major cardiovascular events began to emerge with increases >2 ng/L. Further work is needed to better characterize the biological variation in hsTn over time and determine how biological variation may impact categorization with respect to the risk of future events in clinical practice. 23, 24 Risk stratification using serial measurements should take into account both the starting and follow-up values. It is not surprising that those patients with undetectable hsTnI at the 2 points in time over 6 months were at low risk of cardiac events within the next 2 years. However, the low risk in this population despite their recent presentation with ACS is noteworthy.
The ability of hsTnI to identify patients at higher risk for a variety of cardiovascular events, including cardiovascular death, has important prognostic and potential treatment implications. The majority of prevention strategies utilized in clinical practice identify patients at increased risk using only the demographics, lipid levels, and past medical history. 25, 26 Patients with elevated hsTnI in the EXAMINE trial were at increased risk of both ischemic and HF events, indicating that hsTnI likely reflects the influence of both risk factors for atherosclerosis and underlying myocardial stress in stable patients. Our findings provide support for the possibility that serial assessments of hsTnI, a sensitive biomarker of myocardial injury, could be used to add more granularity to current risk models and further refine the estimates of risk for patients with DM who may warrant more aggressive or additional secondary prevention strategies. 2 It is possible that further intensification of secondary prevention strategies may improve outcomes in patients with elevated hsTnI. For example, we and others have observed greater absolute benefits of intensive statin therapy in high-risk patients with elevated hsTn. 27, 28 In addition, the information afforded by serial undetectable values of hsTn may be useful in weighing risks versus the magnitude of absolute benefit with some therapies used in secondary prevention. For example, patients with DM have been shown to benefit from prolonged duration of more potent antithrombotic therapy after an MI. However, the benefit with prolonged antiplatelet therapies with regard to a reduction in ischemic events must be weighed against the risk of bleeding. [29] [30] [31] Thus, the use of hsTnI to personalize treatment strategies warrants further study.
Application of hsTn in Trials of Cardiovascular Safety
The findings from this study also reinforce the primary results of EXAMINE with respect to the cardiovascular safety of alogliptin. Although previous studies have found that agents used in the treatment of DM may increase the risk of cardiovascular events, 32 the EXAMINE trial met its primary safety end point supporting the overall cardiovascular safety of alogliptin. 10 When baseline hsTnI was used to identify a subgroup of patients at considerable risk of cardiovascular events, treatment with alogliptin neither increased nor decreased the risk of ischemic or HF events. These results are consistent with earlier findings, which found that patients treated with alogliptin did not have differences in N-terminal pro-brain natriuretic peptide levels when compared with placebo nor was the risk of HF higher in those patients with the highest quartile of N-terminal pro-brain natriuretic peptide. 12 
Additional Clinical Implications
The most recent universal definition of MI emphasizes that providers must consider the clinical context of patients in whom biomarkers are measured and found to be elevated. 33 In this study of patients with T2DM who had known ischemic heart disease and were stable without other clinical evidence of unstable ischemic disease, 16% had levels of hsTnI ˃99th percentile URL for the assay used in this study. These findings highlight the need to consider the clinical context and to determine whether there is an acutely rising or falling pattern of cardiac troponin concentration when ruling in or ruling out the MI diagnosis. The measurement of these biomarkers in patients who have DM or stable ischemic heart disease and who lack clinical evidence of acute myocardial ischemia increases the possibility of identifying patients with chronic myocardial injury without acute infarction.
Limitations
Our study should be considered within the context of its limitations. First, the EXAMINE trial included patients hsTnI, high-sensitivity cardiac troponin I. Hazard ratio was adjusted for baseline hsTnI, age, sex, index event, time from index event, history of heart failure, renal function, baseline HbA1c, and hypertension; 189 patients have baseline hsTnI ˂1.9 ng/L but not equal to 1.8 ng/L, and 115 patients have 6-month hsTnI ˂1.9 ng/L but not equal to 1.8 ng/L. We imputed these values to 1.8 ng/L. *Kaplan Meier rate at 30 months.
with T2DM who had a recent ACS, and the prognostic relationship with hsTnI at baseline and 6 months may not be applicable in other patient populations. Furthermore, few cardiovascular events occurred in those patients with undetectable or extremely low hsTnI, resulting in wide CIs around the estimated risk. Last, we do not have data that permit us to adjust for the severity of coronary artery disease or left ventricular mass.
CONCLUSIONS
The majority of patients with T2DM and established ischemic heart disease have detectable levels of hsTnI, and 16% of patients have hsTnI levels that are above the clinical decision limit for MI. The magnitude of hsTnI elevation, regardless of whether measured 1 to 3 months after ACS or 6 months later, is an independent predictor of both ischemic and HF events. Serial assessment of hsTn enhanced risk stratification and revealed a substantial proportion of patients without clinically recognized decompensation who had either dynamic rising or persistently elevated values and were at high risk of recurrent major cardiovascular events. We found no evidence that alogliptin increased the risk of major cardiovascular events compared with placebo even in those patients identified as being extremely high risk based on the degree of hsTnI elevation. These data contribute to the evolving understanding of potential applications of hsTn for prognostication in patients with T2DM.
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